• Home
  • Respiratory diseases Publications

Respiratory diseases Publications

Respiratory diseases Publications

  • No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study.Abstract

    To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Neterlands, the Danish population registers, and the IMS Real-World Evidence Longitudinal Patient Database panels in France

    Rebordosa C, Houben E, Laugesen K, Bothner U, Montonen J, Aguado J, Overbeek JA, Ehrenstein V, Asmar J, Wallace L, Gilsenan AW. Sci Rep. 2020 Jan 17; 10 586.
  • Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids.Abstract

    PURPOSE: Extrafine-particle inhaled corticosteroids (ICS) have greater small airway deposition than standard fine-particle ICS. We sought to compare asthma-related outcomes after patients initiated extrafine-particle ciclesonide or fine-particle IC(fluticasone propionate or non-extrafine beclomethasone)

    Postma DS, Dekhuijzen R, van der Molen T, Martin RJ, van Aalder en W, Roche N, Guilbert TW, Israel E, van Eickels D, Khalid JM, Herings RM, Overbeek JA, Miglio C, Thomas V, Hutton C, Hillyer EV, Price DB. Allergy Asthma Immunol Res. 2017 Mar; 9 (2): 116-125.
  • An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthma.Abstract

    BACKGROUND: Cohort matching and regression modeling are used in observational studies to control for confounding factors when estimating treatment effects. Our objective was to evaluate exact matching and propensity score methods by applying them ia 1-year pre-post historical database study to investigate asthma-related outcomes by treatment

    Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RM, Overbeek JA, Khalid JM, van Eickels D, Price DB. Pragmat Obs Res. 2017 8 15-30.
  • Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes.Abstract

    OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 1years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System

    Ahmadizar F, Souverein PC, Arets HG, deBoer A, Maitland-van der Zee AH. Pediatr Pulmonol. 2016 Nov; 51 (11): 1113-1121.
  • Non-adherence to inhaled corticosteroids and the risk of asthma exacerbations in children.Abstract

    BACKGROUND: Non-adherence to inhaled corticosteroids (ICSs) is a major risk factor for poor asthma control in children. However, little is known about the effect of adherence to ICS on the incidence of asthma exacerbations. The objective of this stdy was to examine the effect of poor adherence to ICS on the risk of exacerbations in children with asthma

    Vasbinder EC, Belitser SV, Souverein PC, van Dijk L, Vulto AG, van den Bemt PM. Patient Prefer Adherence. 2016 10 531-8.
  • Effectiveness of initiating extrafine-particle versus fine-particle inhaled corticosteroids as asthma therapy in the Netherlands.Abstract

    BACKGROUND: Most randomised clinical trials typically exclude a significant proportion of asthma patients, including those at higher risk of adverse events, with comorbidities, obesity, poor inhaler technique and adherence, or smokers. However, thee patients might differentially benefit from extrafine-particle inhaled corticosteroids (ICS)

    van der Molen T, Postma DS, Martin RJ, Herings RM, Overbeek JA, Thomas V, Miglio C, Dekhuijzen R, Roche N, Guilbert T, Israel E, van Aalder en W, Hillyer EV, van Rysewyk S, Price DB. BMC Pulm Med. 2016 16 (1): 80.
  • Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.Abstract

    AIM: Palivizumab is reported to be effective in reducing respiratory syncytial virus hospitalisation. Its licensed uses include infants younger than six months of age, born before 35 weeks of gestation or under two years old with congenital heart dsease or bronchopulmonary dysplasia. We redressed lack of research in the Netherlands by studying whether infants who met the licensed indications received the drug

    Kool-Houweling LM, Penning-van Beest FJ, Bezemer ID, van Lingen RA, Herings RM. Acta Paediatr. 2015 Sep; 104 (9): 927-32.
  • Burden of Exacerbations in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-life Study.Abstract

    OBJECTIVE: The objective of this study was to compare rates of different types of acute exacerbations of COPD (AECOPDs) and healthcare utilization among patients with different severities of COPD. METHODS: Data for this study was obtained from theHARMO Database Network, which includes drug dispensing records from pharmacies, hospitalization records and information from general practitioners

    Overbeek JA, Penning-van Beest FJ, Balp MM, Dekhuijzen PN, Herings RM. COPD. 2015 Apr; 12 (2): 132-43.
  • Antibiotic prescribing on admission to patients with pneumonia and prior outpatient antibiotic treatment: a cohort study on clinical outcome.Abstract

    OBJECTIVE: Most pneumonia treatment guidelines recommend that prior outpatient antibiotic treatment should be considered when planning inpatient antibiotic regimen. Our purpose was to study in patients admitted for community-acquired pneumonia theode of continuing antibiotic treatment at the outpatient to inpatient transition and the subsequent clinical course

    van deGarde EM, Natsch S, Prins JM, van der Linden PD. BMJ Open. 2015 5 (2): e006892.
  • Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study.Abstract

    BACKGROUND: We aimed to determine whether (1) patients with obstructive pulmonary disease (OPD) have an increased risk of sudden cardiac arrest (SCA) due to ventricular tachycardia or fibrillation (VT/VF), and (2) the SCA risk is mediated by cardioascular risk-profile and/or respiratory drug use. METHODS: A community-based case-control study was performed, with 1310 cases of SCA of the ARREST study and 5793 age, sex and SCA-date matched non-SCA controls from the PHARMO database

    Warnier MJ, Blom MT, Bardai A, Berdowksi J, Souverein PC, Hoes AW, Rutten FH, de Boer A, Koster RW, DeBruin ML, Tan HL. PLoS One. 2013 8 (6): e65638.